首页> 外文学位 >Investigating Crystallization tendency, Miscibility and Molecular interactions of drug-polymer systems for the development of amorphous solid dispersions.
【24h】

Investigating Crystallization tendency, Miscibility and Molecular interactions of drug-polymer systems for the development of amorphous solid dispersions.

机译:研究用于形成无定形固体分散体的药物-聚合物体系的结晶趋势,互溶性和分子相互作用。

获取原文
获取原文并翻译 | 示例

摘要

This project aims to characterize the crystallization tendencies, miscibility and molecular interaction in drug-polymer systems of poorly soluble drugs and correlate it with the performance of prepared or reported SDs (solid dispersions). Crystallization tendencies of five different drugs [i.e. Curcumin (CUR), indomethacin (IND), flutaminde (FLU), dipyridamole (DIP), griseofulvin (GRI)] in absence and presence of four different polymers [i.e. polyethylene glycol (PEG), eudragit EPO (EPO), hydroxypropyl methylcellulose (HPMC) and polyvinyl pyrrolidone (PVP)] in various drug-polymer ratios were determined by using modulated differential scanning calorimetry (MDSC). Thermal analysis i.e. glass transition temperature (Tg), crystallinity and melting point depression along with theoretical calculations such as solubility parameter were performed to study drug polymer miscibility. Molecular interactions were predicted by using Tg deviations and molecular modeling. Physical states of drug in the SDs were characterized by X-ray diffraction (XRD) and MDSC. IR (Infrared) and Raman were used in selected systems (i.e. CUR, DIP and GRI systems) to explore the role of drug polymer interactions in amorphization of SDs. Dissolution studies using USP apparatus II and physical stability study at room temperature were performed for selected systems. Based on the absence and presence of endothermic and exothermic peaks (heat-cool-heat cycle) in MDSC, the crystallization tendency of pure drugs was categorized as low, moderate and high. In presence of selected polymers, crystallization tendency of all the drugs can be modified albeit high polymer concentration was required for drugs with high crystallization tendency i.e. DIP and GRI (> 50%w/w). Polymers showing greater effect on crystallization tendency of drugs were found to have higher drug-polymer miscibility and stronger molecular interactions. For example, FLU-PVP system showed good miscibility and no remarkable Tg deviation. This is reflected in its ability to change the crystallization tendency of FLU. Further, the results correlated well with the physical state, dissolution and stability of prepared/reported SDs. The developed approach has significant potential to be a rational screening method for the development of amorphous SDs.
机译:该项目旨在表征难溶性药物在药物-聚合物系统中的结晶趋势,可混溶性和分子相互作用,并将其与已制备或报告的SD(固体分散体)的性能相关联。五种不同药物的结晶趋势[即姜黄素(CUR),吲哚美辛(IND),氟他胺(FLU),双嘧达莫(DIP),灰黄霉素(GRI)]在没有和存在四种不同聚合物的情况下[即通过使用调制差示扫描量热法(MDSC)确定了各种药物-聚合物比例下的聚乙二醇(PEG),古灵芝EPO(EPO),羟丙基甲基纤维素(HPMC)和聚乙烯吡咯烷酮(PVP)]。进行了热分析,即玻璃化转变温度(Tg),结晶度和熔点降低以及诸如溶度参数的理论计算,以研究药物聚合物的溶混性。通过使用Tg偏差和分子模型预测分子相互作用。通过X射线衍射(XRD)和MDSC对SD中药物的物理状态进行了表征。在选定的系统(即CUR,DIP和GRI系统)中使用了IR(红外)和拉曼光谱,以探索药物聚合物相互作用在SD非晶化中的作用。对于选定的系统,使用USP设备II进行了溶出度研究,并在室温下进行了物理稳定性研究。基于MDSC中不存在吸热和放热峰(热-冷-热循环),将纯药物的结晶趋势分为低,中和高。在存在选定的聚合物的情况下,尽管对于具有高结晶趋势的药物,即DIP和GRI(> 50%w / w),需要高聚合物浓度,但可以改变所有药物的结晶趋势。发现对药物的结晶趋势显示更大影响的聚合物具有更高的药物-聚合物混溶性和更强的分子相互作用。例如,FLU-PVP系统显示出良好的混溶性,并且没有明显的Tg偏差。这反映在其改变FLU的结晶趋势的能力上。此外,结果与制备/报告的SD的物理状态,溶解和稳定性很好地相关。所开发的方法具有很大的潜力,可以作为开发非晶态SD的合理筛选方法。

著录项

  • 作者

    Meng, Fan.;

  • 作者单位

    Creighton University.;

  • 授予单位 Creighton University.;
  • 学科 Pharmaceutical sciences.
  • 学位 M.S.
  • 年度 2015
  • 页码 153 p.
  • 总页数 153
  • 原文格式 PDF
  • 正文语种 eng
  • 中图分类
  • 关键词

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号